MovDisordV3, PascalFrancis, Corpus, bibRecord, 000E48

Nigrostriatal Upregulation of 5-HT2A Receptors Correlates with Motor Dysfunction in Progressive Supranuclear Palsy

Identifieur interne : 000E48 ( PascalFrancis/Corpus ); précédent : 000E47; suivant : 000E49

Nigrostriatal Upregulation of 5-HT2A Receptors Correlates with Motor Dysfunction in Progressive Supranuclear Palsy

Auteurs : Maria Stamelou ; Andreas Matusch ; David Elmenhorst ; René Hurlemann ; Karla M. Eggert ; Karl Zilles ; Wolfgang H. Oertel ; Günter U. Höglinger ; Andreas Bauer

Source :

Movement disorders [ 0885-3185 ] ; 2009.

RBID : Pascal:09-0301991

Descripteurs français

Pascal (Inist)
- Pathologie du système nerveux, Récepteur sérotoninergique 5-HT2A, Trouble fonctionnel, Sérotonine, Tomoscintigraphie, Tomographie par émission de positons.

English descriptors

KwdEn :
- 5-HT2A serotonin receptor, Dysfunction, Emission tomography, Nervous system diseases, Positron emission tomography, Serotonin.

Abstract

A dysfunction of multiple neurotransmitter systems is assumed as a neurochemical basis of the akinetic-rigid syndrome of progressive supranuclear palsy (PSP). In vitro studies have produced conflicting results on the serotoninergic system in PSP. We, therefore, studied the binding potential of the serotonin 2A (5-HT_2A) receptor ligand [¹⁸F]altanserin in 8 patients with clinically probable PSP and 13 healthy controls using positron emission tomography. We found an up-regulation of 5-HT_2A receptors in the substantia nigra and, to a lower degree, in the striatum, while neocortical 5- HT_2A receptor densities showed no changes upon partial-volume correction. Nigral and striatal receptor changes were significantly correlated with patients' scores of motor dysfunction (UPDRS III, PSP-rating scale) pointing to a functional relevance of the described findings.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 24`
A06				`@2 8`
A08	`01`	`1`	`ENG`	`@1 Nigrostriatal Upregulation of 5-HT_2A Receptors Correlates with Motor Dysfunction in Progressive Supranuclear Palsy`
A11	`01`	`1`		`@1 STAMELOU (Maria)`
A11	`02`	`1`		`@1 MATUSCH (Andreas)`
A11	`03`	`1`		`@1 ELMENHORST (David)`
A11	`04`	`1`		`@1 HURLEMANN (René)`
A11	`05`	`1`		`@1 EGGERT (Karla M.)`
A11	`06`	`1`		`@1 ZILLES (Karl)`
A11	`07`	`1`		`@1 OERTEL (Wolfgang H.)`
A11	`08`	`1`		`@1 HÖGLINGER (Günter U.)`
A11	`09`	`1`		`@1 BAUER (Andreas)`
A14	`01`			`@1 Institute of Neuroscience and Biophysics-Medicine (INB-3), Research Center Jülich @2 Jülich @3 DEU @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 6 aut. @Z 9 aut.`
A14	`02`			`@1 Department of Neurology, Philipps University @2 Marburg @3 DEU @Z 1 aut. @Z 2 aut. @Z 5 aut. @Z 7 aut. @Z 8 aut.`
A14	`03`			`@1 Department of Psychiatry, University of Bonn @2 Bonn @3 DEU @Z 4 aut.`
A14	`04`			`@1 C. & O. Vogt Institute for Brain Research, University of Düsseldorf @2 Düsseldorf @3 DEU @Z 6 aut.`
A14	`05`			`@1 Department of Neurology, University of Düsseldorf @2 Düsseldorf @3 DEU @Z 9 aut.`
A20				`@1 1170-1175`
A21				`@1 2009`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000196165080090`
A44				`@0 0000 @1 © 2009 INIST-CNRS. All rights reserved.`
A45				`@0 18 ref.`
A47	`01`	`1`		`@0 09-0301991`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 A dysfunction of multiple neurotransmitter systems is assumed as a neurochemical basis of the akinetic-rigid syndrome of progressive supranuclear palsy (PSP). In vitro studies have produced conflicting results on the serotoninergic system in PSP. We, therefore, studied the binding potential of the serotonin 2A (5-HT_2A) receptor ligand [¹⁸F]altanserin in 8 patients with clinically probable PSP and 13 healthy controls using positron emission tomography. We found an up-regulation of 5-HT_2A receptors in the substantia nigra and, to a lower degree, in the striatum, while neocortical 5- HT_2A receptor densities showed no changes upon partial-volume correction. Nigral and striatal receptor changes were significantly correlated with patients' scores of motor dysfunction (UPDRS III, PSP-rating scale) pointing to a functional relevance of the described findings.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B17G`
C03	`01`	`X`	`FRE`	`@0 Pathologie du système nerveux @5 01`
C03	`01`	`X`	`ENG`	`@0 Nervous system diseases @5 01`
C03	`01`	`X`	`SPA`	`@0 Sistema nervioso patología @5 01`
C03	`02`	`X`	`FRE`	`@0 Récepteur sérotoninergique 5-HT2A @5 09`
C03	`02`	`X`	`ENG`	`@0 5-HT2A serotonin receptor @5 09`
C03	`02`	`X`	`SPA`	`@0 Receptor serotoninérgico 5-HT2A @5 09`
C03	`03`	`X`	`FRE`	`@0 Trouble fonctionnel @5 10`
C03	`03`	`X`	`ENG`	`@0 Dysfunction @5 10`
C03	`03`	`X`	`SPA`	`@0 Trastorno funcional @5 10`
C03	`04`	`X`	`FRE`	`@0 Sérotonine @2 NK @2 FR @5 11`
C03	`04`	`X`	`ENG`	`@0 Serotonin @2 NK @2 FR @5 11`
C03	`04`	`X`	`SPA`	`@0 Serotonina @2 NK @2 FR @5 11`
C03	`05`	`X`	`FRE`	`@0 Tomoscintigraphie @5 12`
C03	`05`	`X`	`ENG`	`@0 Emission tomography @5 12`
C03	`05`	`X`	`SPA`	`@0 Tomocentelleografía @5 12`
C03	`06`	`X`	`FRE`	`@0 Tomographie par émission de positons @5 13`
C03	`06`	`X`	`ENG`	`@0 Positron emission tomography @5 13`
C03	`06`	`X`	`SPA`	`@0 Tomografía emisión positrones @5 13`
C07	`01`	`X`	`FRE`	`@0 Neurotransmetteur @5 37`
C07	`01`	`X`	`ENG`	`@0 Neurotransmitter @5 37`
C07	`01`	`X`	`SPA`	`@0 Neurotransmisor @5 37`
N21				`@1 215`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 09-0301991 INIST
ET :	Nigrostriatal Upregulation of 5-HT_2A Receptors Correlates with Motor Dysfunction in Progressive Supranuclear Palsy
AU :	STAMELOU (Maria); MATUSCH (Andreas); ELMENHORST (David); HURLEMANN (René); EGGERT (Karla M.); ZILLES (Karl); OERTEL (Wolfgang H.); HÖGLINGER (Günter U.); BAUER (Andreas)
AF :	Institute of Neuroscience and Biophysics-Medicine (INB-3), Research Center Jülich/Jülich/Allemagne (1 aut., 2 aut., 3 aut., 6 aut., 9 aut.); Department of Neurology, Philipps University/Marburg/Allemagne (1 aut., 2 aut., 5 aut., 7 aut., 8 aut.); Department of Psychiatry, University of Bonn/Bonn/Allemagne (4 aut.); C. & O. Vogt Institute for Brain Research, University of Düsseldorf/Düsseldorf/Allemagne (6 aut.); Department of Neurology, University of Düsseldorf/Düsseldorf/Allemagne (9 aut.)
DT :	Publication en série; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2009; Vol. 24; No. 8; Pp. 1170-1175; Bibl. 18 ref.
LA :	Anglais
EA :	A dysfunction of multiple neurotransmitter systems is assumed as a neurochemical basis of the akinetic-rigid syndrome of progressive supranuclear palsy (PSP). In vitro studies have produced conflicting results on the serotoninergic system in PSP. We, therefore, studied the binding potential of the serotonin 2A (5-HT_2A) receptor ligand [¹⁸F]altanserin in 8 patients with clinically probable PSP and 13 healthy controls using positron emission tomography. We found an up-regulation of 5-HT_2A receptors in the substantia nigra and, to a lower degree, in the striatum, while neocortical 5- HT_2A receptor densities showed no changes upon partial-volume correction. Nigral and striatal receptor changes were significantly correlated with patients' scores of motor dysfunction (UPDRS III, PSP-rating scale) pointing to a functional relevance of the described findings.
CC :	002B17; 002B17G
FD :	Pathologie du système nerveux; Récepteur sérotoninergique 5-HT2A; Trouble fonctionnel; Sérotonine; Tomoscintigraphie; Tomographie par émission de positons
FG :	Neurotransmetteur
ED :	Nervous system diseases; 5-HT2A serotonin receptor; Dysfunction; Serotonin; Emission tomography; Positron emission tomography
EG :	Neurotransmitter
SD :	Sistema nervioso patología; Receptor serotoninérgico 5-HT2A; Trastorno funcional; Serotonina; Tomocentelleografía; Tomografía emisión positrones
LO :	INIST-20953.354000196165080090
ID :	09-0301991

Links to Exploration step

Pascal:09-0301991

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Nigrostriatal Upregulation of 5-HT<sub>2A</sub>
 Receptors Correlates with Motor Dysfunction in Progressive Supranuclear Palsy</title>
<author><name sortKey="Stamelou, Maria" sort="Stamelou, Maria" uniqKey="Stamelou M" first="Maria" last="Stamelou">Maria Stamelou</name>
<affiliation><inist:fA14 i1="01"><s1>Institute of Neuroscience and Biophysics-Medicine (INB-3), Research Center Jülich</s1>
<s2>Jülich</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Department of Neurology, Philipps University</s1>
<s2>Marburg</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Matusch, Andreas" sort="Matusch, Andreas" uniqKey="Matusch A" first="Andreas" last="Matusch">Andreas Matusch</name>
<affiliation><inist:fA14 i1="01"><s1>Institute of Neuroscience and Biophysics-Medicine (INB-3), Research Center Jülich</s1>
<s2>Jülich</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Department of Neurology, Philipps University</s1>
<s2>Marburg</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Elmenhorst, David" sort="Elmenhorst, David" uniqKey="Elmenhorst D" first="David" last="Elmenhorst">David Elmenhorst</name>
<affiliation><inist:fA14 i1="01"><s1>Institute of Neuroscience and Biophysics-Medicine (INB-3), Research Center Jülich</s1>
<s2>Jülich</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hurlemann, Rene" sort="Hurlemann, Rene" uniqKey="Hurlemann R" first="René" last="Hurlemann">René Hurlemann</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Psychiatry, University of Bonn</s1>
<s2>Bonn</s2>
<s3>DEU</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Eggert, Karla M" sort="Eggert, Karla M" uniqKey="Eggert K" first="Karla M." last="Eggert">Karla M. Eggert</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Neurology, Philipps University</s1>
<s2>Marburg</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Zilles, Karl" sort="Zilles, Karl" uniqKey="Zilles K" first="Karl" last="Zilles">Karl Zilles</name>
<affiliation><inist:fA14 i1="01"><s1>Institute of Neuroscience and Biophysics-Medicine (INB-3), Research Center Jülich</s1>
<s2>Jülich</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>C. & O. Vogt Institute for Brain Research, University of Düsseldorf</s1>
<s2>Düsseldorf</s2>
<s3>DEU</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Oertel, Wolfgang H" sort="Oertel, Wolfgang H" uniqKey="Oertel W" first="Wolfgang H." last="Oertel">Wolfgang H. Oertel</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Neurology, Philipps University</s1>
<s2>Marburg</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hoglinger, Gunter U" sort="Hoglinger, Gunter U" uniqKey="Hoglinger G" first="Günter U." last="Höglinger">Günter U. Höglinger</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Neurology, Philipps University</s1>
<s2>Marburg</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bauer, Andreas" sort="Bauer, Andreas" uniqKey="Bauer A" first="Andreas" last="Bauer">Andreas Bauer</name>
<affiliation><inist:fA14 i1="01"><s1>Institute of Neuroscience and Biophysics-Medicine (INB-3), Research Center Jülich</s1>
<s2>Jülich</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="05"><s1>Department of Neurology, University of Düsseldorf</s1>
<s2>Düsseldorf</s2>
<s3>DEU</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">09-0301991</idno>
<date when="2009">2009</date>
<idno type="stanalyst">PASCAL 09-0301991 INIST</idno>
<idno type="RBID">Pascal:09-0301991</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000E48</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Nigrostriatal Upregulation of 5-HT<sub>2A</sub>
 Receptors Correlates with Motor Dysfunction in Progressive Supranuclear Palsy</title>
<author><name sortKey="Stamelou, Maria" sort="Stamelou, Maria" uniqKey="Stamelou M" first="Maria" last="Stamelou">Maria Stamelou</name>
<affiliation><inist:fA14 i1="01"><s1>Institute of Neuroscience and Biophysics-Medicine (INB-3), Research Center Jülich</s1>
<s2>Jülich</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Department of Neurology, Philipps University</s1>
<s2>Marburg</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Matusch, Andreas" sort="Matusch, Andreas" uniqKey="Matusch A" first="Andreas" last="Matusch">Andreas Matusch</name>
<affiliation><inist:fA14 i1="01"><s1>Institute of Neuroscience and Biophysics-Medicine (INB-3), Research Center Jülich</s1>
<s2>Jülich</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Department of Neurology, Philipps University</s1>
<s2>Marburg</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Elmenhorst, David" sort="Elmenhorst, David" uniqKey="Elmenhorst D" first="David" last="Elmenhorst">David Elmenhorst</name>
<affiliation><inist:fA14 i1="01"><s1>Institute of Neuroscience and Biophysics-Medicine (INB-3), Research Center Jülich</s1>
<s2>Jülich</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hurlemann, Rene" sort="Hurlemann, Rene" uniqKey="Hurlemann R" first="René" last="Hurlemann">René Hurlemann</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Psychiatry, University of Bonn</s1>
<s2>Bonn</s2>
<s3>DEU</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Eggert, Karla M" sort="Eggert, Karla M" uniqKey="Eggert K" first="Karla M." last="Eggert">Karla M. Eggert</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Neurology, Philipps University</s1>
<s2>Marburg</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Zilles, Karl" sort="Zilles, Karl" uniqKey="Zilles K" first="Karl" last="Zilles">Karl Zilles</name>
<affiliation><inist:fA14 i1="01"><s1>Institute of Neuroscience and Biophysics-Medicine (INB-3), Research Center Jülich</s1>
<s2>Jülich</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>C. & O. Vogt Institute for Brain Research, University of Düsseldorf</s1>
<s2>Düsseldorf</s2>
<s3>DEU</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Oertel, Wolfgang H" sort="Oertel, Wolfgang H" uniqKey="Oertel W" first="Wolfgang H." last="Oertel">Wolfgang H. Oertel</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Neurology, Philipps University</s1>
<s2>Marburg</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hoglinger, Gunter U" sort="Hoglinger, Gunter U" uniqKey="Hoglinger G" first="Günter U." last="Höglinger">Günter U. Höglinger</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Neurology, Philipps University</s1>
<s2>Marburg</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bauer, Andreas" sort="Bauer, Andreas" uniqKey="Bauer A" first="Andreas" last="Bauer">Andreas Bauer</name>
<affiliation><inist:fA14 i1="01"><s1>Institute of Neuroscience and Biophysics-Medicine (INB-3), Research Center Jülich</s1>
<s2>Jülich</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="05"><s1>Department of Neurology, University of Düsseldorf</s1>
<s2>Düsseldorf</s2>
<s3>DEU</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2009">2009</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>5-HT2A serotonin receptor</term>
<term>Dysfunction</term>
<term>Emission tomography</term>
<term>Nervous system diseases</term>
<term>Positron emission tomography</term>
<term>Serotonin</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Pathologie du   système nerveux</term>
<term>Récepteur sérotoninergique 5-HT2A</term>
<term>Trouble fonctionnel</term>
<term>Sérotonine</term>
<term>Tomoscintigraphie</term>
<term>Tomographie par émission de positons</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">A dysfunction of multiple neurotransmitter systems is assumed as a neurochemical basis of the akinetic-rigid syndrome of progressive supranuclear palsy (PSP). In vitro studies have produced conflicting results on the serotoninergic system in PSP. We, therefore, studied the binding potential of the serotonin 2A (5-HT<sub>2A</sub>
) receptor ligand [<sup>18</sup>
F]altanserin in 8 patients with clinically probable PSP and 13 healthy controls using positron emission tomography. We found an up-regulation of 5-HT<sub>2A</sub>
 receptors in the substantia nigra and, to a lower degree, in the striatum, while neocortical 5- HT<sub>2A</sub>
 receptor densities showed no changes upon partial-volume correction. Nigral and striatal receptor changes were significantly correlated with patients' scores of motor dysfunction (UPDRS III, PSP-rating scale) pointing to a functional relevance of the described findings.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>24</s2>
</fA05>
<fA06><s2>8</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Nigrostriatal Upregulation of 5-HT<sub>2A</sub>
 Receptors Correlates with Motor Dysfunction in Progressive Supranuclear Palsy</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>STAMELOU (Maria)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>MATUSCH (Andreas)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>ELMENHORST (David)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>HURLEMANN (René)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>EGGERT (Karla M.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>ZILLES (Karl)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>OERTEL (Wolfgang H.)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>HÖGLINGER (Günter U.)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>BAUER (Andreas)</s1>
</fA11>
<fA14 i1="01"><s1>Institute of Neuroscience and Biophysics-Medicine (INB-3), Research Center Jülich</s1>
<s2>Jülich</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Neurology, Philipps University</s1>
<s2>Marburg</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Department of Psychiatry, University of Bonn</s1>
<s2>Bonn</s2>
<s3>DEU</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>C. & O. Vogt Institute for Brain Research, University of Düsseldorf</s1>
<s2>Düsseldorf</s2>
<s3>DEU</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Department of Neurology, University of Düsseldorf</s1>
<s2>Düsseldorf</s2>
<s3>DEU</s3>
<sZ>9 aut.</sZ>
</fA14>
<fA20><s1>1170-1175</s1>
</fA20>
<fA21><s1>2009</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000196165080090</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2009 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>18 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>09-0301991</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>A dysfunction of multiple neurotransmitter systems is assumed as a neurochemical basis of the akinetic-rigid syndrome of progressive supranuclear palsy (PSP). In vitro studies have produced conflicting results on the serotoninergic system in PSP. We, therefore, studied the binding potential of the serotonin 2A (5-HT<sub>2A</sub>
) receptor ligand [<sup>18</sup>
F]altanserin in 8 patients with clinically probable PSP and 13 healthy controls using positron emission tomography. We found an up-regulation of 5-HT<sub>2A</sub>
 receptors in the substantia nigra and, to a lower degree, in the striatum, while neocortical 5- HT<sub>2A</sub>
 receptor densities showed no changes upon partial-volume correction. Nigral and striatal receptor changes were significantly correlated with patients' scores of motor dysfunction (UPDRS III, PSP-rating scale) pointing to a functional relevance of the described findings.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Pathologie du   système nerveux</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Récepteur sérotoninergique 5-HT2A</s0>
<s5>09</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>5-HT2A serotonin receptor</s0>
<s5>09</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Receptor serotoninérgico 5-HT2A</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Trouble fonctionnel</s0>
<s5>10</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Dysfunction</s0>
<s5>10</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Trastorno funcional</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Sérotonine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>11</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Serotonin</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>11</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Serotonina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Tomoscintigraphie</s0>
<s5>12</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Emission tomography</s0>
<s5>12</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Tomocentelleografía</s0>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Tomographie par émission de positons</s0>
<s5>13</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Positron emission tomography</s0>
<s5>13</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Tomografía emisión positrones</s0>
<s5>13</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Neurotransmetteur</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Neurotransmitter</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Neurotransmisor</s0>
<s5>37</s5>
</fC07>
<fN21><s1>215</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 09-0301991 INIST</NO>
<ET>Nigrostriatal Upregulation of 5-HT<sub>2A</sub>
 Receptors Correlates with Motor Dysfunction in Progressive Supranuclear Palsy</ET>
<AU>STAMELOU (Maria); MATUSCH (Andreas); ELMENHORST (David); HURLEMANN (René); EGGERT (Karla M.); ZILLES (Karl); OERTEL (Wolfgang H.); HÖGLINGER (Günter U.); BAUER (Andreas)</AU>
<AF>Institute of Neuroscience and Biophysics-Medicine (INB-3), Research Center Jülich/Jülich/Allemagne (1 aut., 2 aut., 3 aut., 6 aut., 9 aut.); Department of Neurology, Philipps University/Marburg/Allemagne (1 aut., 2 aut., 5 aut., 7 aut., 8 aut.); Department of Psychiatry, University of Bonn/Bonn/Allemagne (4 aut.); C. & O. Vogt Institute for Brain Research, University of Düsseldorf/Düsseldorf/Allemagne (6 aut.); Department of Neurology, University of Düsseldorf/Düsseldorf/Allemagne (9 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2009; Vol. 24; No. 8; Pp. 1170-1175; Bibl. 18 ref.</SO>
<LA>Anglais</LA>
<EA>A dysfunction of multiple neurotransmitter systems is assumed as a neurochemical basis of the akinetic-rigid syndrome of progressive supranuclear palsy (PSP). In vitro studies have produced conflicting results on the serotoninergic system in PSP. We, therefore, studied the binding potential of the serotonin 2A (5-HT<sub>2A</sub>
) receptor ligand [<sup>18</sup>
F]altanserin in 8 patients with clinically probable PSP and 13 healthy controls using positron emission tomography. We found an up-regulation of 5-HT<sub>2A</sub>
 receptors in the substantia nigra and, to a lower degree, in the striatum, while neocortical 5- HT<sub>2A</sub>
 receptor densities showed no changes upon partial-volume correction. Nigral and striatal receptor changes were significantly correlated with patients' scores of motor dysfunction (UPDRS III, PSP-rating scale) pointing to a functional relevance of the described findings.</EA>
<CC>002B17; 002B17G</CC>
<FD>Pathologie du   système nerveux; Récepteur sérotoninergique 5-HT2A; Trouble fonctionnel; Sérotonine; Tomoscintigraphie; Tomographie par émission de positons</FD>
<FG>Neurotransmetteur</FG>
<ED>Nervous system diseases; 5-HT2A serotonin receptor; Dysfunction; Serotonin; Emission tomography; Positron emission tomography</ED>
<EG>Neurotransmitter</EG>
<SD>Sistema nervioso patología; Receptor serotoninérgico 5-HT2A; Trastorno funcional; Serotonina; Tomocentelleografía; Tomografía emisión positrones</SD>
<LO>INIST-20953.354000196165080090</LO>
<ID>09-0301991</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E48 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000E48 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:09-0301991
   |texte=   Nigrostriatal Upregulation of 5-HT2A Receptors Correlates with Motor Dysfunction in Progressive Supranuclear Palsy
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Nigrostriatal Upregulation of 5-HT2A Receptors Correlates with Motor Dysfunction in Progressive Supranuclear Palsy

Nigrostriatal Upregulation of 5-HT2A Receptors Correlates with Motor Dysfunction in Progressive Supranuclear Palsy

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri